Annovis Bio, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ANVS New York 2836 www.annovisbio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Annovis Bio, Inc.

Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group - Dec 3rd, 2025 6:00 am
Annovis Announces Two Presentations at the CTAD 2025 Conference - Nov 24th, 2025 6:00 am
Annovis Announces FDA Meeting to Discuss Parkinson's Disease Dementia Program; Reaffirms FDA Alignment on Pivotal Phase 3 Alzheimer's Disease Study - Nov 18th, 2025 6:00 am
Annovis Reports New Biomarker Data Linking Amyloid Co-Pathology to Accelerated Cognitive Decline in Parkinson's Patients - Nov 17th, 2025 6:00 am
Annovis Provides Corporate Updates and Reports Third Quarter 2025 Financial Results - Nov 12th, 2025 6:00 am
Annovis Achieves Significant Milestones and Sustains Strong Progress in Phase 3 Alzheimer’s Program - Nov 6th, 2025 6:00 am
Annovis Announces $3.4 Million Registered Direct Offering of Common Stock Priced At-the-Market under the NYSE Rules - Oct 27th, 2025 6:00 am
Annovis Announces Closing of $6 Million Registered Direct Offering of Common Stock - Oct 15th, 2025 3:15 pm
Annovis Announces $6 Million Registered Direct Offering of Common Stock - Oct 10th, 2025 6:31 am
Annovis Announces Novel Biomarker Data in Alzheimer’s Patients Supporting Buntanetap’s Potential as a Disease-Modifying Treatment - Oct 9th, 2025 5:30 am
Annovis Appoints Mark Guerin as Chief Financial Officer - Sep 25th, 2025 5:30 am
Annovis Reports Peer-Reviewed Publication Highlighting Pharmacokinetics of Novel Crystal Buntanetap - Sep 16th, 2025 5:30 am
Annovis to Present at the H.C. Wainwright 27th Annual Global Investment Conference - Sep 2nd, 2025 6:00 am
Annovis (ANVS) Secures Patent Coverage for Both Forms of Buntanetap - Aug 29th, 2025 5:24 am
Annovis Provides Corporate Updates and Reports Second Quarter 2025 Financial Results - Aug 12th, 2025 2:05 pm
Annovis Completes Full Patent Transfer to Crystal Buntanetap - Aug 7th, 2025 6:00 am
Annovis to Attend the AAIC 2025 with Four Poster Presentations - Jun 26th, 2025 6:00 am
We Think Annovis Bio (NYSE:ANVS) Needs To Drive Business Growth Carefully - Jun 22nd, 2025 8:30 am
Annovis Announces NYSE Acceptance of Plan to Regain Listing Compliance - Jun 19th, 2025 4:30 am
All You Need to Know About Annovis Bio (ANVS) Rating Upgrade to Buy - Jun 11th, 2025 10:00 am